Literature DB >> 10561333

Gemcitabine is active in relapsed Hodgkin's disease.

J B Lucas, S M Horwitz, S J Horning, A Sayegh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10561333

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

1.  Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.

Authors:  O Sezer; J Eucker; C Jakob; O Kaufmann; P Schmid; K Possinger
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

2.  Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.

Authors:  Sally Arai; Renee Letsinger; Ruby M Wong; Laura J Johnston; Ginna G Laport; Robert Lowsky; David B Miklos; Judith A Shizuru; Wen-Kai Weng; Philip W Lavori; Karl G Blume; Robert S Negrin; Sandra J Horning
Journal:  Biol Blood Marrow Transplant       Date:  2010-03-01       Impact factor: 5.742

3.  Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.

Authors:  J H Mendler; J Kelly; S Voci; D Marquis; L Rich; R M Rossi; S H Bernstein; C T Jordan; J Liesveld; R I Fisher; J W Friedberg
Journal:  Ann Oncol       Date:  2008-05-25       Impact factor: 32.976
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.